Re-Evaluating the Potential Impact and Cost-Effectiveness of Rotavirus Vaccination in 73 Gavi Countries: A Modelling Study
This article, published in The Lancet Global Health, reports the results of a modelling analysis to provide updated cost-effectiveness estimates to inform national decisions about the new introduction and current use of rotavirus vaccines in Gavi, the Vaccine Alliance-eligible countries. The results indicate that over the period of 2018-2027, rotavirus vaccination has the potential to prevent nearly 600,000 deaths in Gavi countries, and averted outpatient visits and hospitalizations could lead to treatment savings of approximately US$484.1 million from the governmental perspective and US$878 million from the societal perspective. The authors conclude that rotavirus vaccination continues to represent good value for money across most Gavi countries despite lower rotavirus mortality estimates and more stringent willingness-to-pay thresholds.
Author: Debellut F, Clark A, Pecenka C, et al.
» Visit web page (English)
(Located at www.thelancet.com)
Citation: Debellut F, Clark A, Pecenka C, et al. Re-Evaluating the Potential Impact and Cost-Effectiveness of Rotavirus Vaccination in 73 Gavi Countries: A Modelling Study. The Lancet Global Health. 2019;7(12):PE1664-E1674.
Resource types: Peer-reviewed journal